Evidence map›Paper›PMID 38793733›Full record

ArticleVaccines2024

Antibody Response after Homologous and Heterologous Prime-Boost COVID-19 Vaccination in a Bangladeshi Residential University Cohort.

Nihad Adnan, Md Ahsanul Haq, Salma Akter, S M Shafiul Alam Sajal, Md Fokhrul Islam, Taslin Jahan Mou, Mohd Raeed Jamiruddin, Fatema Tuz Jubyda, Md Salequl Islam, Jamsheda Ferdous Tuli and 10 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Vaccines, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Nihad AdnanDepartment of Microbiology, Jahangirnagar University, Savar, Dhaka 1342, Bangladesh.ORCID 0000-0002-4999-4793
Md Ahsanul HaqRNA Biotech Limited, Dhaka 1209, Bangladesh.ORCID 0000-0002-4408-6104
Salma AkterDepartment of Microbiology, Jahangirnagar University, Savar, Dhaka 1342, Bangladesh.ORCID 0000-0002-2901-7784
S M Shafiul Alam SajalGonoshasthaya-RNA Biotech Limited, Dhaka 1205, Bangladesh.
Md Fokhrul IslamInstitute of Quantitative Biology, Biochemistry and Biotechnology, School of Biological Sciences, University of Edinburgh, Edinburgh EH9 3FF, UK.
Taslin Jahan MouDepartment of Microbiology, Jahangirnagar University, Savar, Dhaka 1342, Bangladesh.
Mohd Raeed JamiruddinSchool of Pharmacy, BRAC University, Dhaka 1212, Bangladesh.ORCID 0000-0003-0495-4808
Fatema Tuz JubydaDepartment of Microbiology, Jahangirnagar University, Savar, Dhaka 1342, Bangladesh.
Md Salequl IslamDepartment of Microbiology, Jahangirnagar University, Savar, Dhaka 1342, Bangladesh.ORCID 0000-0001-6131-4132
Jamsheda Ferdous TuliDepartment of Microbiology, Jahangirnagar University, Savar, Dhaka 1342, Bangladesh.ORCID 0009-0009-1848-3753
Syeda Moriam LizaDepartment of Microbiology, Jahangirnagar University, Savar, Dhaka 1342, Bangladesh.
Sharif HossainDepartment of Biotechnology & Genetic Engineering, Jahangirnagar University, Savar, Dhaka 1342, Bangladesh.ORCID 0000-0001-7763-4616
Zinia IslamDepartment of Biotechnology & Genetic Engineering, Jahangirnagar University, Savar, Dhaka 1342, Bangladesh.
Sohel AhmedDepartment of Biochemistry & Molecular Biology, Jahangirnagar University, Savar, Dhaka 1342, Bangladesh.
Shahad Saif KhandkerGonoshasthaya-RNA Biotech Limited, Dhaka 1205, Bangladesh.ORCID 0000-0003-4724-0645
Rubel HossainGonoshasthaya-RNA Biotech Limited, Dhaka 1205, Bangladesh.ORCID 0000-0003-3805-7101
Md Firoz AhmedDepartment of Microbiology, Jahangirnagar University, Savar, Dhaka 1342, Bangladesh.
Mohib Ullah KhondokerGonoshasthaya-RNA Biotech Limited, Dhaka 1205, Bangladesh.
Nafisa AzmudaDepartment of Microbiology, Jahangirnagar University, Savar, Dhaka 1342, Bangladesh.
Md Anowar Khasru ParvezDepartment of Microbiology, Jahangirnagar University, Savar, Dhaka 1342, Bangladesh.ORCID 0000-0002-0246-3872

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

COVID-19 vaccination strategies, including heterologous prime-boost regimens and additional booster doses, aim to optimize immune responses. However, seroepidemiological studies on immune responses to different COVID-19 vaccine types and schedules remain limited. This study investigated antibody levels following homologous and heterologous prime-and-boost COVID-19 vaccination in Bangladesh. In a cohort of 606 participants who received first/second/booster doses of vaccines (AstraZeneca, Moderna, Pfizer-BioNTech, and Sinopharm), anti-spike IgG and anti-nucleocapsid IgG levels were measured. Antibody titer variations with respect to age, gender, intervals between doses, and prior infection status were analyzed. mRNA vaccines elicited the highest antibody levels after homologous and heterologous boosting. The AstraZeneca booster resulted in a sharp titer decline rate of ~0.04 units per day. Second or booster vaccine doses significantly increased antibody levels, especially in males (

Indexed as

COVID-19 vaccinationheterologous booster doseheterologous prime and boosthumoral immunity

Identifiers

PMID38793733
PMCPMC11125736

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.